Therefore, experimental designs should integrate spatial and multi-omics pharmacodynamic indicators, such as the reduction of TAM-tumor-CAF neighbor clusters, decreased TREM2 or SPP1 TAM load, and normalization of CCL2, IL10, and TGFB. This evidence concerns the gene IL10 and neoplasm.